Cost Effectiveness Debate Now Features The Body Bag Argument

Center for Medicine in the Public Interest contends that over five years, 44,000 fewer patients will be alive if ICER's cost-effectiveness calculation for multiple myeloma treatments is adopted.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet